We are united in purpose.

The history of our success lies in our ability to apply it to the future. We are pioneering science in the field of virus-specific T cell (VST) therapies and embrace a shared commitment to our mission to prevent and defeat life-threatening viral diseases.

We champion truth and challenge the status quo in pursuit of continuous improvement in the fight against viral diseases. Our innovative spirit lives beyond the lab, in a world where everyone has access to a healthy immune system.

Immunity for All.

Our Leadership

Diana M. Brainard, MD
Chief Executive Officer
Diana Brainard, MD has more than 20 years of experience in academic medicine and the biopharmaceutical industry, has authored more than 200 publications, and brings a passion for advancing therapies for life-threatening diseases.
Vikas Sinha
President and Chief Financial Officer
Vikas Sinha is AlloVir's President and Chief Financial Officer and brings over 25 years of experience in executive finance roles within the biopharmaceutical industry.
Ann Leen, PhD
Chief Scientific Officer
For more than 20 years, Dr. Ann Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies.
Agustin Melian, MD
Chief Medical Officer & Head of Global Medical Sciences
Prior to joining AlloVir, Dr. Augustin Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals.
Jeroen van Beek, PhD
Chief Commercial Officer
Jeroen van Beek is responsible for commercial strategy, planning and operations at AlloVir. Before joining AlloVir, Dr. van Beek was the Chief Commercial Officer and Senior Vice-President at Tricida.
Ercem Atillasoy, MD
Chief Regulatory and Safety Officer
Dr. Atillasoy, Chief Regulatory and Safety Officer, has nearly 25 years of experience leading drug, biologic, and infectious disease product development.
Edward Miller
General Counsel
Edward Miller has more than 25 years of diverse legal and business experience in the biotechnology and pharmaceutical industry and related fields.
Sonia Choi
Senior Vice President, Corporate Affairs and Investor Relations
Ms. Choi brings more than two decades of experience leading global, regional, and in-market communications within the biopharmaceutical industry.
Dana Alexander, MBA
Senior Vice President, Technical Operations
Mr. Alexander brings more than 20 years of experience in biopharmaceutical operations for start-up, late clinical-stage, and commercial biologic products.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now

Board of Directors

Jeffrey Bornstein
Managing Partner at Generation Capital Partners and Founder and Principal of Whipstick Ventures LLC
Mr. Bornstein serves as a managing partner of Whipstick Ventures and Generation Capital, and was the Chief Financial Officer and Vice Chairman of General Electric until October 2017.
Diana M. Brainard, MD
Chief Executive Officer
Diana Brainard, MD has more than 20 years of experience in academic medicine and the biopharmaceutical industry, has authored more than 200 publications, and brings a passion for advancing therapies for life-threatening diseases.
Malcolm Brenner, MD, PhD
Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Dr. Brenner is the founding director of the Center for Cell and Gene Therapy and the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics.
Ansbert Gadicke, MD
Co-founder and Managing Director, MPM Ventures
Dr. Ansbert Gadicke is co-founder and Managing Director of MPM and its venture capital activities, Managing Partner of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities managed by MPM.
David Hallal
Executive Chairman of the Board
David Hallal is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies.
Morana Jovan-Embiricos, PhD
Managing Partner, F2 Ventures
Dr. Jovan co-founded F2 Ventures, a biotech venture capital platform, in 2003 and has since served as its Managing Partner.
Vikas Sinha
President and Chief Financial Officer
Vikas Sinha is AlloVir's President and Chief Financial Officer and brings over 25 years of experience in executive finance roles within the biopharmaceutical industry.
Juan F. Vera, MD
Associate Professor, Baylor College of Medicine
Dr. Juan Vera has more than 15 years of experience performing research in the field of adoptive T cell therapy and has made several contributions in the field.
John Wilson
CEO, Wilson Wolf Manufacturing Corporation
Mr. Wilson has over 30 years of experience in the design, development, and manufacture of products for the field of biotechnology, including cell culture devices and bioreactors.

Advisors

Malcolm Brenner, MD, PhD
Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Dr. Brenner is the founding director of the Center for Cell and Gene Therapy and the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics.
Mitchell H. Finer, PhD
Senior Scientific Advisor
Dr. Finer has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine for the last three decades.
Helen Heslop, MD, DSC
SAB Member, Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Dr. Heslop is Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital.
Cliona Rooney, PhD
SAB Member, Professor of Pediatrics, Baylor College of Medicine
Dr. Rooney is a Professor in the Departments of Pediatrics, Molecular Virology and Microbiology, and Immunology and Director of Translational Research Laboratories at the Center for Cell and Gene Therapy at Baylor College of Medicine.
Elizabeth Stoner, MD, MS
Senior Clinical Advisor
A distinguished biopharma executive, Liz Stoner is an MPM Executive Partner who brings decades of international industry experience to her role guiding and growing MPM’s and its affiliated portfolio companies.

Life @ AlloVir

You want your life outside the lab to be as purposeful as your life inside it.  We have the benefits to support you.
PTO Policies
Making sure that you have the freedom to time off when you need to is an important part of our culture. Life beyond the lab includes a flexible approach to PTO; you take it when you need it.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
401k Plans
We offer 401(k) matching, employer-paid life short and long-term disability, and life insurance.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
Healthcare
Our health plans include medical, vision, and dental covered at 90%, as well as Flexible Spending Accounts (FSA) and Dependent Care Accounts (DCA).
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
Family Leave
Growing and taking care of your family is as important as the work you do. We offer a generous parental leave program that allows you to do just that.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now
Cell phone and commuter reimbursement
Being connected and getting where you need to go is an important part of your work. We offer cell phone and commuter reimbursement programs that acknowledge the time you spend in and out of the office.
Life @AlloVir
Trust, commitment, and the drive to build something together. Interested in being part of our vision? Check out our open positions.
Apply Now

AlloVir is the global leader in developing VST immunotherapies

We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses as treatment or prevention.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

We are united in purpose around a singular mission to prevent and defeat life-threatening viral diseases.
meet
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?